Acetyl-11-keto-β-boswellic acid alleviates hepatic metabolic dysfunction by inhibiting MGLL activity

Kai Luan, Yuhong Fan, Qin Yang, Hailong Yang, Zelin Zhou, Ju Huang, Zhi‐Gang She, Toujun Zou, Hui Xiong, Zhinan MeiJournal of Lipid Research 2025 · DOI

TL;DR

This study identifies acetyl-11-keto-β-boswellic acid (AKBA), a natural compound from Boswellia carterii, as a potent inhibitor of monoacylglycerol lipase (MGLL). AKBA effectively alleviates NAFLD and related metabolic dysfunction in mouse models by directly targeting and inhibiting MGLL in hepatocytes, suggesting its potential as a novel therapeutic for these conditions.

What Problem Does This Paper Address?

Nonalcoholic fatty liver disease (NAFLD) and its associated metabolic disorders, like obesity and insulin resistance, are major global health challenges. Despite their prevalence, effective pharmaceutical treatments are limited. Current approved therapies for NASH (a more severe form of NAFLD) have suboptimal efficacy. This research addresses the urgent need for novel therapeutic targets and drugs to combat NAFLD and its related metabolic complications. The study specifically investigates the potential of natural compounds, particularly those from Traditional Chinese Medicine, to offer safer and more effective treatment options.

Methods

The researchers employed a multi-pronged approach combining in vitro and in vivo experiments:

  • Cellular Assays: Primary hepatocytes were used to assess AKBA's cytotoxicity and its effects on lipid accumulation and inflammation induced by a high-fat/high-cholesterol (PO) diet. Techniques included CCK-8 assays for viability, Oil Red O (ORO) staining for lipid droplets, and quantitative PCR (qPCR) for gene expression analysis.
  • Animal Models: Two mouse models were utilized:
  • NAFLD Model: Induced by a high-fat diet (HFD) for 24 weeks.
  • NASH Model: Induced by a high-fat, high-cholesterol (HFHC) diet for 16 weeks.
  • MGLL Knockout (KO) Models: Used to specifically investigate the role of MGLL in AKBA's therapeutic effects.
  • Omics Analyses:
    • RNA Sequencing (RNA-seq): Performed on liver samples from HFHC-fed mice to identify differentially expressed genes and pathways affected by AKBA.
  • Proteomic Analysis: Used mass spectrometry to identify differentially expressed proteins between AKBA-treated and control groups.
  • Biochemical and Histological Analyses: Standard methods were used to measure serum lipid profiles (TC, TG, LDL-c), liver enzymes (ALT, AST), glucose tolerance (GTT), and assess liver histology (H&E, ORO, PSR staining for fibrosis, and CD11b staining for inflammation).
  • Molecular Interaction Studies:
    • Biotinylation and Pull-down Assays: Used to confirm the direct interaction between AKBA and MGLL.
  • Isothermal Titration Calorimetry (ITC): Quantified the binding affinity between AKBA and purified MGLL protein.
  • Molecular Docking: Predicted the specific amino acid residues on MGLL involved in binding with AKBA.
  • Enzyme Assays: Measured MGLL activity using LC-MS to determine the effect of AKBA on its enzymatic function.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • AKBA as a Novel MGLL Inhibitor: The study unequivocally identifies AKBA as a direct inhibitor of MGLL, a key enzyme in lipid metabolism. This is a significant finding as it pinpoints a specific molecular target for AKBA's beneficial effects.
  • MGLL's Central Role in AKBA's Efficacy: The experiments with MGLL-deficient mice are crucial. The complete abrogation of AKBA's therapeutic effects in these mice strongly underscores that MGLL inhibition is not just one mechanism, but the primary mechanism by which AKBA exerts its protective effects against NAFLD/NASH.
  • Natural Compounds as Targeted Therapeutics: This research highlights the potential of natural compounds like AKBA to act as highly specific inhibitors of key enzymes, offering a promising avenue for developing targeted therapies with potentially fewer side effects than synthetic drugs.
  • Multi-faceted Benefits of AKBA: AKBA doesn't just address one aspect of NAFLD; it simultaneously mitigates lipid accumulation, inflammation, and fibrosis, suggesting a comprehensive approach to tackling this complex disease.
  • Structural Basis for Interaction: The identification of specific amino acid residues (GLU60, MET64, THR279, and PHE283) involved in AKBA binding to MGLL provides a molecular blueprint for understanding and potentially designing even more potent inhibitors.

Key Results

  • In Vitro: AKBA significantly reduced lipid accumulation and inflammation in primary hepatocytes treated with a high-fat/high-cholesterol (PO) diet. It also modulated the expression of key genes involved in lipid metabolism and inflammation.
  • In Vivo (NAFLD Model): AKBA treatment in HFD-fed mice led to significant reductions in body weight, liver weight, hepatic steatosis (reduced NAS score and ORO staining), and improved glucose tolerance. Serum lipid profiles (TC, TG, LDL-c) and liver enzymes (ALT, AST) were also significantly improved.
  • In Vivo (NASH Model): In HFHC-fed mice, AKBA attenuated body and liver weight gain, reduced hepatic steatosis and congestion, improved glucose tolerance, and decreased NAS scores. It also reduced liver TG content and serum lipid levels, and importantly, reduced liver fibrosis (PSR staining) and inflammation (CD11b staining).
  • MGLL Knockout Studies: In both in vitro and in vivo settings, the absence of MGLL completely abolished AKBA's beneficial effects, confirming MGLL as the essential target.
  • Binding Affinity: ITC analysis showed a high-affinity interaction between AKBA and MGLL (Kd of 4.06 × 10⁻⁵ mol/L).
  • Molecular Docking: Identified key amino acid residues (GLU60, MET64, THR279, PHE283) in MGLL critical for AKBA binding.

Limitations and Future Work

  • Focus on Liver Tissue: The authors acknowledge that their study primarily focused on liver tissue. While in vitro data strongly suggest direct effects on hepatocytes, the potential contributions of other tissues to the observed improvements in fatty liver remain unexplored. Future work could investigate systemic effects.
  • Weight Loss as a Factor: While weight loss was observed in animal models, the in vitro data demonstrating direct effects on hepatocytes suggest that AKBA's action is not solely dependent on systemic weight reduction. However, further studies could more precisely disentangle the contributions of direct hepatic effects versus systemic metabolic changes.
  • Broader Therapeutic Potential: The authors suggest that given AKBA's known anti-inflammatory and antioxidant properties, it might hold promise for conditions beyond NAFLD/NASH, such as liver transplantation and ischemia-reperfusion injury. Further investigation into these areas is warranted.
  • Developing MGLL Inhibitors: The study provides a strong rationale for developing MGLL inhibitors for liver diseases. Future research could focus on optimizing AKBA or developing novel, potent, and safe MGLL inhibitors for clinical application.

Summary updated

Abstract

Metabolic abnormalities have emerged as a central pathogenesis in various metabolic diseases, particularly nonalcoholic fatty liver disease (NAFLD) and its associated complications of obesity and insulin resistance. Despite this, effective pharmaceutical treatments for NAFLD-related metabolic disorders remain limited. In this study, we identified acetyl-11-keto-beta-boswellic acid (AKBA), a natural compound isolated from the gum resin of Boswellia carterii, showing robust capacity against NAFLD as well as its related body weight gain and insulin resistance. Our findings demonstrate that the beneficial effects of AKBA on metabolic disorders are largely dependent on its direct interaction with monoacylglycerol lipase (MGLL) in hepatocytes. In vivo experiments using a high-fat and high-cholesterol (HFHC) diet-induced NAFLD mouse model revealed that AKBA effectively mitigated both the progression of NAFLD and associated metabolic dysfunctions. Proteomic and RNA sequencing analyses further elucidated that AKBA attenuates key pathways related to lipid accumulation, inflammation, and fibrosis. Mechanistically, AKBA was found to directly target MGLL in hepatocytes, inhibiting its activity in hydrolyzing monoacylglycerols. Structural analyses revealed that AKBA binds specifically to the GLU60, MET64, THR279, and PHE283 residues of MGLL. Importantly, AKBA showed no additional therapeutic effect in MGLL-deficient models, underscoring the crucial role of MGLL in mediating AKBA's therapeutic action. In conclusion, our study identifies AKBA as a novel and potent MGLL inhibitor and suggests that it holds promise as a therapeutic candidate for NAFLD and related metabolic diseases. This research highlights the potential of natural compounds in the development of targeted treatments for metabolic disorders.
BibTeX
@article{luan2025acetyl,
  author = {Kai Luan and Yuhong Fan and Qin Yang and Hailong Yang and Zelin Zhou and Ju Huang and Zhi‐Gang She and Toujun Zou and Hui Xiong and Zhinan Mei},
  title = {{Acetyl-11-keto-β-boswellic acid alleviates hepatic metabolic dysfunction by inhibiting MGLL activity}},
  journal = {Journal of Lipid Research},
  year = {2025},
  doi = {10.1016/j.jlr.2025.100812},
}
Figure